Amyloid-β PET and CSF Aβ42 yield discordant results in 10-20% of patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic and imaging features for amyloid-positivity has previously been investigated, it is unknown whether these features differentially predict amyloid-β status based on PET or CSF, or whether this differs by disease stage.
Exploring this allows us to gain insight in the clinical and neurobiological factors related to discordant results between amyloid-β PET and CSF and ultimately about the underlying neuropathological processes during the disease course of AD.
METHODS:

Study Population
We retrospectively included 777 patients, who had visited our tertiary memory clinic between 2005 and 2017 and had undergone both CSF Aβ42 analysis and amyloid-β PET within one year. We excluded nine patients that did not pass PET imaging quality control. Patients were screened according to the standardized protocol of the Amsterdam Dementia Cohort (22, 23) . This includes a clinical and neuropsychological evaluation, APOE genotyping, MR imaging and a lumbar puncture for CSF analysis.
Patient diagnosis was determined during a multidisciplinary meeting, according to international guidelines (10, 11, (24) (25) (26) (27) (28) (29) (30) (31) (32) .
Neuropsychological testing
Subjects underwent extensive neuropsychological testing as part of their diagnostic process. Mini-Mental State Examination (MMSE) scores were used to measure global cognition. In addition, five cognitive domains were assessed (33) . We used the visual association test (VAT), total immediate recall, and the For every test, we derived Z-scores using the mean and standard deviation values from a group of healthy controls (n = 360) (33) . TMT-A, TMT-B and Stroop Test scores were log-transformed to account for the non-normal distribution of the data and multiplied by -1 so that lower scores would indicate worse performance. In case TMT B was aborted and TMT A was available (n = 132), we estimated the TMT B score using the multiplication of TMT A score with mean TMT B/A score ratio from the respective diagnostic group (34) . Thereafter, based on available tests we used z-scores to compile a composite score for each of the five cognitive domains. CSF CSF was obtained by lumbar puncture between L3/4, L4/5 or L5/S1 intervertebral space, using a 25-gauge needle and a syringe (35) . The samples were collected in polypropylene microtubes and centrifuged at 1800g for 10min at 4°C. Thereafter, the samples were frozen at -20 °C until manual analyses of Ab42, tau and p-tau were performed using sandwich ELISAs [Innotest assays: β-amyloid1-42, tTAU-Ag and PhosphoTAU-181p; Fujirebio (formerly Innogenetics)] at the Neurochemistry Laboratory of the Department of Clinical Chemistry of VUmc. As the median CSF Aβ42 values of our cohort have been gradually increasing over the years (36) , we determined CSF amyloid-β status using Aβ42 values that had been adjusted for the longitudinal upward drift. We used a uniform cut-off of 813 pg/mL to dichotomize CSF data, as continuous measures were not available for PET imaging (37).
PET
Amyloid-β PET scanning is not part of standard diagnostic process in the Amsterdam Dementia Cohort.
Patients underwent an amyloid-β PET for research purposes in the vast majority (38) (39) (40) (41) (42) (43) or otherwise in case of a diagnostic dilemma. Amyloid-β PET scans were performed using the following PET scanners:
ECAT EXACT HR+ scanner (Siemens Healthcare, Germany) and Gemini TF PET/CT, Ingenuity TF PET-CT and Ingenuity PET/MRI (Philips Medical Systems, the Netherlands). We included PET scans using four different radiotracers: [ 18 F]Florbetaben (38, 43) 
MRI
The acquisition of MRI scans has been extensively described previously (23) . During the period of 2005 to 2017, the following scanners have been used: Discovery MR750 and Signa HDXT (both GE Medical Systems, USA); Ingenuity TF PET/MR (Philips Medical Systems, The Netherlands); Titan (Toshiba Medical Systems, Japan); Magnetom Impact and Sonata (Siemens Healthcare, Germany). The MRI protocol included 3D T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR), gradient-echo T2* and/or susceptibility weighted imaging sequences. The scans were visually assessed by a neuroradiologist on three different image planes. Parietal atrophy was rated using the posterior cortical atrophy (PCA) scale (45) , medial temporal atrophy using the medial temporal lobe atrophy (MTA) scale (46) and the extent of white matter hyperintensities according to the Fazekas scale (47) . MTA and PCA scores were scored separately for right and left and averaged thereafter. In addition, the scans were assessed for the existence of lacunes and microbleeds.
Patient groups
We stratified the patients based on syndrome diagnosis: subjective cognitive decline (SCD, n=194 (29%)) (48), mild cognitive impairment (MCI, n=127 (17%)), and dementia (n=447 (58%)). Within the dementia group, 309 (69%) patients had the diagnosis of Alzheimer's disease, 66 (15%) a diagnosis within the frontotemporal dementia spectrum, 22 (5%) dementia with Lewy bodies, 6 (1%) vascular dementia and 44 (10%) other dementia syndromes. To reflect the information provided to the models in our analysis, we present patient group characteristics based on the binarized amyloid-β status on PET and CSF: concordantly positive (PET+/CSF+) or negative (PET-/CSF-for amyloid-β pathology, or discordantly positive amyloid-β status based on PET (PET+/CSF-) or CSF (PET/CSF+).
Statistical Analysis
Statistical analysis was performed using R software (Version 3.4.4) (49). When presenting our study population by binarized PET/CSF status groups, we compared patient features using Chi-squared tests, two samples t-tests, Wilcoxon Rank-Sum tests and linear regression models with Bonferroni correction for group-wise testing. Cognitive scores were compared while adjusting for age, sex, education and syndrome diagnosis.
All subsequent analyses were performed in the total patient group as well as in the syndrome diagnosis groups of SCD, MCI and dementia. We first summarized the relative predictive power of every variable in predicting PET and CSF amyloid-β status using random forest modelling. As classifier models are affected by missing data, we accounted for missing values using multiple imputations (with 25 imputations and 5 iterations) ( Supplementary Table 1 ). For each of the imputed dataset, we ran two conditional random forest models (50,51), predicting separately PET and CSF status using various patient features associated with Alzheimer's disease (17) (18) (19) . As predictors, we selected demographic information (age, sex, education), biomarkers (APOE ε4 positivity, CSF tau and p-tau), cognitive measures (MMSE; z-scores for memory, language, attention, executive, visuospatial), and MRI scores (MTA, PCA, Fazekas scale, the presence of lacunes and microbleeds). We used the area-under-the-curve (AUC)-based permutation variable importance measure (VIM) to estimate the relative predictive power for every patient feature. This measure was selected because of its higher accuracy in datasets with an unbalanced outcome class (52) and we expected this to be especially helpful in the SCD group with a low prevalence of amyloid-β positivity. Accuracy, sensitivity and specificity of the random forest models were evaluated using the mean out-of-bag error estimates. Using this method, the performance of every tree in the random forest model is evaluated on the approximately 37% of observations that are not used for its training (53) .
For the second stage of the analysis, we selected patient features based on their predictive value in the random forest models. Similar to a previous study (19), we included patient features when their median VIM over the 25 random forests models for predicting either PET or CSF was higher than the median VIM of all the features for the patient group. First, using two sample t-testing of 1000x bootstrapped samples with replacement, we compared the VIM of every selected patient feature between the parallel random forest models predicting amyloid-β PET and CSF status. Secondly, to determine the unadjusted predictive power of these patient features, we performed bivariate logistic regression models with either PET or CSF positivity as the outcome and the selected patient features as predictors. Thirdly, to investigate the added predictive value of a patient feature to the other amyloid-β modality, we performed multivariable logistic regression models, with either PET or CSF positivity as the outcome and the selected patient feature with the status of the other amyloid-β modality as predictors.
We calculated the odds ratios (OR) with corresponding 95% confidence intervals for every patient feature both in the original dataset and in the 25x imputed datasets. Non-overlapping confidence intervals were considered significantly different. We used the False discovery rate (FDR) correction with a significance level of 0.05 to account for multiple testing (54) .
RESULTS:
Overview of features Patient characteristics grouped by PET/CSF status are summarized in Table 1 and CSF Aβ42 levels shown in Figure 1. 32 patients (4%) were discordantly amyloid-β positive based on PET and 65 (8%) based on CSF.
In general, the PET+CSF+ group showed a higher proportion of APOE ε4 carriers, more AD-like CSF markers, MRI features, and lower cognitive scores compared to PET-CSF-group. CSF tau and p-tau were lower in both PET-CSF-and PET-CSF+ groups, compared to PET+CSF-and PET+CSF+. The PET-CSF-group contained a lower proportion of APOE ε4 carriers and better cognitive scores than patients in the discordant groups.
Patient feature selection
We performed random forest modelling to (i) select patient features based on overall VIM for multivariable logistic regression models and (ii) compare the VIM between models predicting PET and CSF amyloid-β status. Summarized VIM values over the 25 random forest models (one with each set of imputed data) are shown in Figure 2 . Out-of-bag accuracy, sensitivity and specificity rates for the random forest models are reported in Supplementary Table 2 . APOE ε4 positivity was the most important predictor for amyloid-β positivity in the total patient group for both PET (VIM=0.28±0.14 (mean VIM*100 ± standard deviation)) and CSF (VIM=0.31±0.19, PET/CSF VIM difference: p=0.51). CSF tau was similarly important when predicting PET (VIM=0.06±0.03) or CSF (VIM=0.06±0.03, p=0.51), but CSF p-tau was a more important predictor for PET (VIM=0.12±0.03) compared to CSF (VIM=0.03±0.01, p<0.001).
Subsequently, we stratified for syndrome diagnosis. In SCD, APOE ε4 positivity was a stronger predictor for CSF (VIM=5.06±0.63) than PET (VIM=1.19±0.18, p<0.001), whereas CSF p-tau was more associated with PET (VIM=1.89±0.29) than CSF amyloid-β status. (VIM=1.44±0.18, p<0.001). Additionally, MMSE (VIM=0.37±0.17) and memory score (VIM=0.66±0.18) had a stronger association with CSF than PET (both p<0.001). CSF tau was equally important for predicting PET (VIM=5.47±0.36) or CSF amyloid-β status (VIM=5.24±0. 38, p=0.13) . In contrast to the findings in SCD, in MCI, APOE ε4 carriership was a stronger predictor for PET (VIM=7.07±0.69) than for CSF (VIM=6.31±0.56, p<0.01). Moreover, CSF tau and p-tau were more important for predicting PET (respectively VIM=6.56±0.42; and VIM=4.90±0.38) than for CSF amyloid-β status (VIM=3.20±0.25, p<0.001; and VIM=2.84±0.21, p<0.001). In dementia, CSF p-tau was more predictive of PET (VIM=1.60±0.32) than CSF (VIM=0.92±0.22, p<0.001), but CSF tau was a stronger predictor for CSF (VIM=0.27±0.07) than for PET amyloid-β status (VIM=0.17±0.04, p<0.001). Both PET (VIM=0.93±0.34) and CSF (VIM=0.97±0.35, p=0.49) had a strong association to APOE ε4 carriership. Finally, visuospatial (VIM=0.37±0.13) and memory (VIM=0.08±0.03) scores were more important for predicting PET positivity (both p<0.001).
We verified the predictive ability of the selected patient features with bivariate logistic regression models for PET and CSF status ( Table 2 ; all possible models in Supplementary Table 3 ). The bivariate models largely confirmed the feature selection of the random forest procedure, as APOE ε4, CSF tau and CSF ptau were consistently significant predictors in all groups. In the total group and dementia, most of the patient features selected based on the random forest models were significant predictors.
Amyloid-adjusted multivariable logistic regression models
We investigated the added predictive value of the selected patient features to the other amyloid-β modality with multivariable logistic regression models ( Table 3 ; all possible models in Supplementary   Table 4 ). We assumed that if PET and CSF would truly provide equal information about amyloid status, additional patient features should never be significant predictors in these models, as the other amyloid status would already provide sufficient predictive power. However, if a patient feature added significant information, this would show a stronger association between the feature and the predicted amyloid-β modality.
The following odds ratios are adjusted for the status of the other amyloid modality. In the total group increased levels of CSF p-tau ( 
DISCUSSION:
We investigated the predictive patterns of various patient features for amyloid-β status based on PET or CSF to determine (i) whether these features have a different association with PET or CSF and (ii) whether this differs per disease stage. We found significant differences in the predictive strength of patient features for amyloid-β status based on PET or CSF. For example, CSF tau, and, especially, CSF p-tau consistently showed a stronger association with amyloid-β status on PET. Additionally, the differential predictive pattern was influenced by the extent of cognitive impairment, as CSF tau was more important in SCD and MCI, while CSF p-tau became more important in the stage of dementia. Moreover, APOE ε4 carriership was more predictive towards CSF status in SCD, whereas it was more predictive towards PET in MCI. These findings suggest that PET and CSF do not provide identical information about the stage of Alzheimer's disease.
The idea to study differences in the predictive strength of patient features for PET/CSF amyloid-β status was based on the differences in characteristics of patients with discordant amyloid-β biomarkers, which have been theorized to be caused by various factors. Possible explanations for the discordance include individual variances in CSF Aβ42 production (55), the composition of amyloid-β plaques (56) , differences in the structure of Aβ fibrils (57), or a variety of technical issues (58,59), including the variability in cut-off values for CSF Aβ42 (14) . It has also been proposed that in the earliest stages of amyloid-β accumulation CSF Aβ42 analysis might be more sensitive, as the decrease in the concentration of soluble isoforms might precede fibrillar amyloid-β plaque deposition detectable by PET (21) . The differences in the predictive pattern found here in relation to other biological variables, such as APOE genotype and (p)tau concentrations, imply that the existence of PET/CSF discordance may not only be due to technical variation, but a reflection of the differences in biological substrate between the modalities. This could also have an effect for future practice in AD research as well as patient care, as the two modalities are currently used as equal alternatives (2, 11) .
We observed that CSF p-tau and tau had a stronger association to amyloid-β based on PET compared to CSF. If we assume that CSF is a more sensitive modality for amyloid-β pathology, then the weaker association with tau could be explained by CSF Aβ42 capturing an earlier stage amyloid-β preceding tau pathology. This was reflected by the predictive patterns in the multivariable logistic regression models: when predicting PET status by CSF status, CSF (p)tau adds information about the added burden of disease (including advancing from CSF+PET-to CSF+PET+). When predicting CSF amyloid-β positivity, however, the existence of amyloid-β pathology on PET already provides sufficient predictive power, of subjects already having reached a later stage in amyloid deposition. Overall, this finding is in accordance with previous work, indicating that PET detects more advanced stages of AD pathology (60) . Although CSF tau and p-tau have been shown to be highly correlated (61) , the results of the random forest models imply that CSF tau is more predictive towards amyloid-β pathology in SCD and MCI, whereas CSF p-tau is more predictive in dementia. This finding might be caused by wider neuronal death preceding the release of phosphorylated tau, although previous work seems to suggest that levels of CSF p-tau decrease in the later stages of AD (62) (63) (64) . Another possible explanation is that this finding is caused by the greater specificity of p-tau for AD pathology (65) , as our cohort also included amyloid-positive patients diagnosed with non-AD dementia, possibly due to secondary amyloid pathology.
Although we focus on the relative differences between PET and CSF, it should be emphasized that in the majority of cases these two modalities contain similar information. This was demonstrated by many of the selected patient features having some predictive power for amyloid-β pathology for both PET and CSF.
Of them, the biological factors APOE ε4 carriership, CSF tau, and p-tau were most consistent in having significant predictive ability amyloid-β status irrespective of the modality. These findings are not unexpected, as APOE ε4 carriership (17, 66, 67) and tau pathology (2, 68) are widely known to have a strong connection to amyloid-β pathology in Alzheimer's disease. Cognitive measures and MRI visual reads showed overall a smaller predictive value towards amyloid-β status, being in concordance with the theory that they show changes downstream of amyloid and tau pathology (69) .
The main strength of our study is the large number of patients with both amyloid-β modalities from a well-characterized cohort. Our study also has several weaknesses. First, due to the stratification by syndrome diagnoses, the outcome of amyloid-β positivity was not equally prevalent. Although we used an AUC-based importance measure that has been shown to be more effective with an unbalanced outcome class (52) , there was still a notably low sensitivity in the SCD group. This could theoretically influence the outcome of the random forest models, although we found comparable results when using logistic regression models. Second, the included patients underwent amyloid-β PET scans with four different radiotracers, allowing for variability in thresholds for amyloid-β positivity. However, this effect is likely reduced by all of the PET scans being visually rated by the same experienced nuclear medicine physician. Third, as continuous measures for PET-imaging were not available, we dichotomized CSF Aβ42 values, causing some loss of information. Fourth, this patient group did not have CSF Aβ40 values available, which have been shown to correct for the individual variation in the production of amyloid-β (70, 71) .
Our findings can be summarized by a hypothetical model highlighting the relative predictive power of patient features towards amyloid-β status based on PET and CSF (Figure 3) . This model supports previous work, suggesting that CSF might be more sensitive in the early stages of amyloid-β pathology, whereas PET status might be more specific to later stages of amyloid-β accumulation. Although the modalities show similar information in the majority of cases, this could have implications for future research and clinical trials. For example, if aiming to capture the earliest stage of amyloid-β pathology, CSF might be preferred over PET. On the contrary, if high confidence of significant amyloid-β pathology is required, PET could be the modality of choice.
CONCLUSION:
We demonstrated that although various patient features have general predictive value towards amyloidβ status, there are finer differences revealed by discordant cases between the predictive pattern for amyloid-β status based on PET and CSF. This indicates that PET-CSF discordance includes valuable information on underlying clinical and neuropathological differences.
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